Full-Time

Software Engineer

Posted on 5/14/2025

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

No salary listed

Junior, Mid

Cambridge, MA, USA

May telecommute up to 1 day per week; 70% in-office structure.

Category
Full-Stack Engineering
Software Engineering
Required Skills
Agile
JavaScript
MySQL
Node.js
TypeScript
AWS
Oracle
AngularJS
Requirements
  • Requires a Master’s degree, or foreign equivalent, in Computer Science, Computer Engineering or related field and 2 years of experience as a Software Developer, Software Engineer, or related position. In the alternative, the employer will accept a Bachelor’s degree, or foreign equivalent, in the specified fields and 5 years of the specified progressive, post-baccalaureate experience.
  • 2 years of experience must include:
  • Using Angular and JavaScript to develop and enhance intuitive user interfaces for web applications;
  • Object oriented programming with Backend Frameworks including .Net;
  • Database Management systems Oracle and MySQL;
  • Cloud computing;
  • Web application performance optimization; and
  • Using Relational Databases to design application features, troubleshoot applications, and build complex data layers.
Responsibilities
  • Collaborate with product owners to design and implement full-stack TypeScript/JavaScript web applications that improve business processes, focusing particularly on the needs of scientific research and administration.
  • Write, test, and debug code, ensuring high reliability and performance across distributed software systems, with a specific emphasis on scalability and resilience.
  • Optimize business and scientific research processes by deploying strategic software development methodologies, enhancing the efficiency of the experimentation design to innovation cycle.
  • Deploy, monitor, and iteratively improve applications within a dynamic cloud environment, ensuring seamless integration and customization for early-development experimentation management.
  • Contribute to many different projects in a dynamic, fast-moving, agile environment, focusing on end-to-end process of developing and delivering a diverse library of low and high throughput lipid nanoparticles (LNPs) and formulations, designed to enable the targeted delivery of mRNA to cells and subsequent protein expression.
  • Engage with scientific user groups to tailor software solutions, facilitating enhanced data capture and comprehensive end-to-end data integration.
  • Apply a broad range of technologies, including TypeScript/JavaScript (Angular and NodeJS), MySQL, and AWS, to develop systems that meet modern data strategy requirements and support organizational goals.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their products work by delivering mRNA into the body, which instructs cells to create specific proteins that can help prevent or treat diseases. This approach is different from traditional medicines, as it leverages the body's own cellular machinery to generate therapeutic proteins. Moderna's goal is to create a new category of medicines that can significantly enhance patient care and improve health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's mRNA platform aligns with the growing trend of personalized medicine.
  • Regulatory approvals in Australia and the UK boost Moderna's market presence for RSV vaccines.
  • AI-driven drug discovery and clinical trials could accelerate Moderna's development processes.

What critics are saying

  • Regulatory scrutiny over trial practices could damage Moderna's reputation and operations.
  • The patent lawsuit with Pfizer and BioNTech poses financial and operational risks.
  • Potential delays in vaccine approvals could hinder Moderna's market entry and growth.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has expanded its pipeline beyond COVID-19 to include RSV and flu vaccines.
  • Moderna collaborates with AI platforms like Benchling to enhance research capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

5%
Things of Business
May 7th, 2025
Benchling and Moderna Collaborate on AI-Driven Research

SAN FRANCISCO and BOSTON, May 7, 2025 - Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna.

Parriva
May 6th, 2025
Flesh-Eating Bacteria Surge in California: What You Need to Know

Moderna is reportedly working on a candidate vaccine using similar mRNA technology to its COVID-19 formula, but experts express concern about regulatory delays.

Labiotech
May 2nd, 2025
From Pandemic Spotlight To Post-Covid Crossroads: What Happened To These Biotech Players?

Newsletter Signup - Under Article / In Page"*" indicates required fields In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility. Riding a surge of public and private funding, they raced to develop vaccines and therapeutics that could curb a once-in-a-century global emergency. While pharma giants like AstraZeneca and Johnson Johnson also played prominent roles, much of the momentum and risk was carried by smaller biotech players suddenly thrown onto the global stage. For a brief moment, it seemed like these companies might reshape the pharmaceutical landscape for good.Fast forward to 2025, and the picture is far more complex.Some, like Moderna and BioNTech, used the momentum to build expansive pipelines beyond COVID-19, branching into cancer, flu, RSV, and other diseases. Others, however, are now scaling down, pivoting, or fading from view entirely. Just this month, companies including GeoVax, CastleVax, and Vaxart revealed they were told to halt their government-backed work on next-generation COVID vaccines under the Biden-era Project NextGen, casting doubt on the long-term strategic value of these initiatives

Pulmonology Advisor
Apr 30th, 2025
HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine

Moderna is testing a pandemic-focused vaccine for avian influenza A(H5N1).

Slay News
Apr 27th, 2025
Moderna Faces Ban for Bribing Children to Join Covid 'Vaccine' Trials

Moderna could face suspension over the practices deemed "unacceptable" by regulators.